- Many approved diabetes drugs and new obesity drugs have been shown to improve cardiometabolic risk factors; however, they have not been rigorously characterized in their cardiovascular profiles.
- The cardiovascular effects of novel compounds can be rigorously assessed in early phase development using advanced imaging and circulating and/or functional methodologies to inform development decisions based on early signs of cardiovascular risk or benefit.
- Robust characterization of the cardiovascular effects of a novel therapy during early development is a safe and cost-effective way to identify potential cardiovascular risk prior to initiating large, expensive phase 3 or 4 cardiovascular outcome trials.
Privacy Overview
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
3rd Party Cookies
This website uses Google Analytics to collect anonymous information, such as the number of visitors to the site, and the most popular pages. Keeping this cookie enabled helps us to improve our website.
Analytics cookies used:
- Google Tag Manager
- GStatic
- Google AdWords
Please enable Strictly Necessary Cookies first so that we can save your preferences!
Privacy Policy
More information about our Cookie Policy can be found within our Privacy Policy